Abstract:Transforming growth factor-b (TGF-b) was initially discovered by its ability to stimulate immortalized fibroblasts to grow in soft agar, a phenotype associated with expressing cancer-causing genes. Subsequently, it became clear that the ‘‘transforming activity’’ of TGF-b is reversible and can have potent cytostatic effects on normal epithelial cells. TGF-b is now well known for its dual effects in cancer progression; while TGF-b can have suppressive effects on normal and premalignant cells, more advanced cancer cells—frequently exposed to high levels of TGF-b produced by themselves or the stroma—are not only resistant to its cytostatic effects but also stimulated in their invasive and metastatic behavior. TGF-b can do this directly by facilitating epithelial tomesenchymal transition (EMT) and indirectly by acting on its surrounding stroma, promoting angiogenesis and immune evasion (Akhurst and Derynck, 2001). TGF-b signals via cell surface TGF-b type I and type II serine threonine kinase receptors and intracellular SMAD effector proteins. Upon TGF-b receptor activation, SMAD2 and SMAD3 become phosphorylated and form heteromeric complexes with SMAD4. These SMAD complexes can accumulate in the nucleus, where they act as transcriptional regulators. Because SMAD2 does not interact with DNA and the affinity of SMAD3 and SMAD4 for DNA is weak, there is a need for SMADs to partner with other DNAbinding transcription factors. The repertoire of SMAD interaction partners is large and diverse, providing a basis for multi-functionality of TGF-b and its context-dependent effects (Massagué, 2012). TGF-b receptors and SMADs are mutated in certain cancers. Inactivation of tumor suppressor genes, activation of proto-oncogenes, and microenvironmental changes can change the tumor suppressive and the tumor promoting activity of the TGF-b receptor/SMAD pathway. Most cancer patients die of metastasis and, because TGF-b is a strong driver of this process, TGF-b pathway inhibiting agents have been developed and tested in clinical trials. However, these compounds inhibit all TGF-b responses and may elicit unwanted effects. Careful selection of patients is warranted and proper biomarkers are needed to select those patients that will benefit from such systemic TGF-b-targeted therapy. A better understanding of the molecular mechanisms underlying the contextual effects of TGF-b in cancer may allow development of therapeutics selectively inhibiting its pro-oncogenic effects. Previously, Yu and colleagues provided some clues on these mechanisms by demonstrating that the phosphoserine/phosphothreonine-binding protein 14-3-3z, which is overexpressed in more than 40% of breast cancers, can potentiate TGF-b/ SMAD signaling during EMT and breast tumor progression (Lu et al., 2009). 14-33z and the tyrosine kinase receptor ErbB2 were found to cooperate in driving non-invasive ductal carcinoma in situ (DCIS) progression to invasive breast ductal carcinoma (IDC). Breast tumors expressing both ErbB2 and 14-3-3z have a higher incidence of metastasis than those expressing only one of them (Lu et al., 2009). In addition, they found 143-3z downregulated the cell cycle inhibitor p27 and activated phosphoinositide 3-kinase, thereby promoting cancer cell proliferation and survival (Rehman et al., 2014 and references therein).

Lack of Responsiveness to Tgf-Beta 1 in A Thyroid Carcinoma Cell Line with Functional Type I and Type Ii Tgf-Beta Receptors and Smad Proteins, Suggests A Novel Mechanism for Tgf-Beta Insensitivity in Carcinoma Cells

Expression of Transforming Growth Factor-β1, Activin A, and Their Receptors in Thyroid Follicle Cells: Negative Regulation of Thyrocyte Growth and Function1.

Expression Of Transforming Growth Factor-Beta 1, Activin A, And Their Receptors In Thyroid Follicle Cells: Negative Regulation Of Thyrocyte Growth And Function

Expression of Transforming-Growth-Factor (Tgf)-Beta Receptors and Smad Proteins in Glioblastoma Cell Lines with Distinct Responses to Tgf-Beta 1

Expression Of Tgf-Beta Related Smad Proteins In Human Epithelial Skin Tumors

Resistance to transforming growth factor–beta occurs in the presence of normal Smad activation

Differential regulation of TGF-β signaling through Smad2, Smad3 and Smad4

Regulation of Cell Proliferation by Smad Proteins

TGF-β inhibits growth of pancreatic ductal epithelial cells through receptor-mediated activation of Smad proteins

TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation

Expressions of type Ⅰ receptor of TGF-β and PCNA in thyroid papillary and follicular carcinomas

Low Transforming Growth Factor-β Pathway Activity in Cervical Adenocarcinomas

The TGF-beta - SMAD pathway is inactivated in cronic lymphocytic leukemia cells

Anaplastic thyroid cancer cell-secreted TGFβ1 plays a key role in inducing macrophage polarization of human monocytes

The Role of TGF-β1 and Mutant SMAD4 on Epithelial-Mesenchymal Transition Features in Head and Neck Squamous Cell Carcinoma Cell Lines

TGF-β Signaling is Often Attenuated During Hepatotumorigenesis, but is Retained for the Malignancy of Hepatocellular Carcinoma Cells.

Expression of apoptosis-related proteins in thyroid tumors and thyroid carcinoma cell lines

The proliferative status of thyrotropes is dependent on modulation of specific cell cycle regulators by thyroid hormone

Cancer Cell Previews 14-3-3 z Turns TGF-b to the Dark Side

Elucidation of Smad Requirement in Transforming Growth Factor-β Type I Receptor-induced Responses

Th9 Cytokines Inhibit Proliferation, Promote Apoptosis, and Immune Escape in Thyroid Carcinoma Cells